AstraZeneca-Bristol Myers Talks Spark Share Moves, Analyst Skepticism

AstraZeneca is in early discussions to acquire Bristol Myers Squibb in a transaction that could reach $400 billion and create one of the world's largest pharmaceutical companies by market value. The talks, first reported by the Financial Times, sent AstraZeneca shares down as much as 7 percent in London trading on Monday, while Bristol Myers shares rose more than 6 percent in U.S. premarket activity.

The proposed combination would pair AstraZeneca, the second-largest listed company in Britain with a market capitalization near 196 billion pounds, with the New Jersey-based cancer drug specialist valued at roughly $133 billion. Together the firms would rank as the fourth-largest drugmaker globally. AstraZeneca declined to comment on the reports, and Bristol Myers did not respond to requests for comment.

Analysts expressed surprise at the potential deal, noting that AstraZeneca has delivered strong growth under chief executive Pascal Soriot since 2012 and is targeting $80 billion in annual sales by 2030. The company has built an extensive pipeline of new medicines without needing external consolidation. Bristol Myers, by contrast, faces the loss of patent protection on key products including the blood thinner Eliquis and the cancer therapy Opdivo, which are expected to bring declining revenue starting next year.

A merger would significantly expand AstraZeneca's footprint in the United States, where the company already plans to invest $50 billion in research and manufacturing by 2030. It would also combine two large oncology portfolios, raising the likelihood of intense regulatory review on both sides of the Atlantic over reduced competition in cancer treatments. Analysts at Jefferies noted that any overlap in oncology assets could trigger scrutiny and that pipeline programs could be obtained through other means without the regulatory and integration risks of a full merger.

The news has revived concerns in Britain about the future of a flagship company that employs thousands and contributes substantially to the national economy. AstraZeneca completed a direct listing on the New York Stock Exchange in June, a step some viewed as preparation for greater American focus. A completed deal could accelerate questions about whether the company's center of gravity is shifting away from the United Kingdom.

Investors appeared to share the uncertainty. AstraZeneca's London-listed shares fell to a session low of 116.46 pounds, weighing on the broader FTSE 100 index. Market reaction reflected doubts that a transaction would deliver clear strategic benefits for AstraZeneca shareholders or patients, particularly given the company's existing momentum and the heavy antitrust barriers that would confront any combination of two major oncology players.

Neither company has confirmed whether the discussions remain active or whether any agreement is likely to be reached.